Evidence map›Paper›PMID 40943437›Full record

ArticleInternational journal of molecular sciences2025

Aqueous Dispersion of Unmodified Fullerene C60: Stimulation of Hair Growth and Study of a New Molecular Target for Interaction.

Nadezda Shershakova, Elena Baraboshkina, Dmitry Khochenkov, Evgeny Turetskiy, Alexandra Nikonova, Oleg Kamyshnikov, Daria Bolyakina, Veronika Parshina, Daria Shabanova, Evelina Makarova and 3 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nadezda ShershakovaNRC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia.ORCID 0000-0001-6444-6499
Elena BaraboshkinaNRC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia.ORCID 0009-0002-0981-5540
Dmitry KhochenkovFSBI "N.N. Blokhin National Medical Research Center for Oncology", Ministry of Health of the Russian Federation, 115522 Moscow, Russia.ORCID 0000-0002-5694-3492
Evgeny TuretskiyNRC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia.ORCID 0000-0002-6822-3409
Alexandra NikonovaNRC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia.ORCID 0000-0001-9610-0935
Oleg KamyshnikovNRC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia.
Daria BolyakinaNRC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia.ORCID 0009-0006-2223-1514
Veronika ParshinaNRC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia.ORCID 0009-0001-7678-2489
Daria ShabanovaNRC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia.
Evelina MakarovaNRC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia.
Sergey AndreevNRC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia.ORCID 0000-0001-8297-579X
Dmitry KudlayNRC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia.ORCID 0000-0003-1878-4467
Musa KhaitovNRC Institute of Immunology FMBA of Russia, 115522 Moscow, Russia.ORCID 0000-0003-4961-9640

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hair loss (alopecia) is a common disorder caused by an interruption in the body's cycle of hair production. This pathology negatively affects the psychoemotional state of patients and significantly reduces their quality of life. The currently available medical treatments (including minoxidil therapy) are effective in arresting the progression of the disease; however, they allow only partial regrowth of hair at best. A significant clinical result occurs only with regular drug use. There is still great interest in finding new drugs for the treatment of alopecia. In this study, we aimed to examine the effect of an aqueous dispersion of unmodified fullerene C60 (ADF) on hair growth. ADF, produced by a unique technology, is biocompatible and non-toxic. Nu/nu mice were subcutaneously injected (2 μg/animal) every two days for a period of 11 days with ADF and, for control purposes, with phosphate-buffered saline (PBS). It was shown that ADF stimulated hair growth. Histological analysis of the nu/nu mice skin areas showed that animals treated with ADF had significantly more (about twice as many) hair follicles in the anagen phase compared to mice treated with PBS. The effect on hair growth persisted even after discontinuation of ADF administration. Analysis of gene expression demonstrated that ADF affected the Wnt-signaling pathway, increased the expression of the

Indexed as

FullerenesHairAlopeciaAnimalsFemaleHair FollicleMaleMiceMice, NudeTumor Necrosis Factor-alphafullerene C60FullerenesTumor Necrosis Factor-alphaadenosine A2A receptorfullerene C60hair growthM2 macrophagesWnt10b

Identifiers

PMID40943437
PMCPMC12429516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.